Metagenomi Therapeutics (MGX) Gains from Investment Securities (2023 - 2025)
Metagenomi (MGX) has disclosed Gains from Investment Securities for 3 consecutive years, with $1.7 million as the latest value for Q4 2025.
- Quarterly Gains from Investment Securities rose 2516.9% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, up 2516.9% year-over-year, with the annual reading at $1.7 million for FY2025, 2516.9% up from the prior year.
- Gains from Investment Securities for Q4 2025 was $1.7 million at Metagenomi, up from $1.3 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $30.6 million in Q1 2023, with the low at $63940.0 in Q1 2024.
- Average Gains from Investment Securities over 3 years is $3.5 million, with a median of $168044.5 recorded in 2023.
- The sharpest move saw Gains from Investment Securities plummeted 99.79% in 2024, then soared 2516.9% in 2025.
- Over 3 years, Gains from Investment Securities stood at $228000.0 in 2023, then plummeted by 71.96% to $63940.0 in 2024, then skyrocketed by 2516.9% to $1.7 million in 2025.
- According to Business Quant data, Gains from Investment Securities over the past three periods came in at $1.7 million, $1.3 million, and $343075.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.